Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGY trial of trimetazidine in asymptomatic hypertrophic cardiomyopathy mutation carriers
NL-OMON52384Phase 2Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Trimetazidine with Placebo (2 arms). Started Mar 2019; status: active, not recruiting.
02
Drugs
trimetazidine
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON52384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52384.